MS
DCOY

Murray Stahl’s Decoy Therapeutics DCOY Stock Holding History

Murray Stahl’s Portfolio DCOY Stock Details DCOY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-22
Closed -$16.4K – 330
2024
Q1 		$16.4K Hold
22
– – ﹤0.01% 322
2023
Q4 		$20.2K Sell
22
-1
-4% -$998 ﹤0.01% 321
2023
Q3 		$21.3K Hold
23
– – ﹤0.01% 324
2023
Q2 		$48.3K Hold
23
– – ﹤0.01% 323
2023
Q1 		$61.9K Buy
+23
New +$74K ﹤0.01% 322
2022
Q4 		– Sell
-2
Closed -$12K – 344
2022
Q3 		$12K Buy
2
+1
+100% +$7.56K ﹤0.01% 328
2022
Q2 		$8K Buy
+1
New +$8.63K ﹤0.01% 336

Other funds holding DCOY

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Murray Stahl's DCOY Position: Q2 2024 in Review

Murray Stahl sold out of Decoy Therapeutics (DCOY) in Q2 2024, closing a stake of 22 shares — an estimated $16.4K sold.

Murray Stahl first reported a position in DCOY in Q2 2022 and held it in 7 quarters. The position peaked at $61.9K in Q1 2023. 3 funds tracked by Wall St. Rank hold DCOY as of Q2 2024.

  • Murray Stahl reported no remaining Decoy Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Murray Stahl sold 22 Decoy Therapeutics shares in Q2 2024, an estimated $16.4K.
  • Murray Stahl first reported a position in Decoy Therapeutics in Q2 2022 and held it in 7 quarters.
  • Murray Stahl's Decoy Therapeutics position peaked at $61.9K in Q1 2023.
  • 3 funds tracked by Wall St. Rank held Decoy Therapeutics as of Q2 2024.

Based on Horizon Kinetics Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.